Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways

Abstract Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hiroshi Hongo, Takeo Kosaka, Yoko Suzuki, Shuji Mikami, Junichi Fukada, Mototsugu Oya
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/56f8f480566741bda2848c462abb3516
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares